John Unitt

John joined Sygnature in August 2011 from AstraZeneca to establish and lead the Bioscience group.

Under his leadership, that department played a key part in their growth and is now home to more than 60 scientists across two sites.

John’s role recently changed to focus on enhancing their capabilities and expertise in inflammation and immunology, and he works to develop their partnerships with customers, investors and project teams in this area.

John is a highly experienced pharmaceutical bioscientist and has worked in a broad range of drug discovery phases from biological target identification and validation, hit identification from multiple sources (e.g. HTS, natural products, fragment-based), novel assay development, hit to lead and lead optimisation.

He worked for AstraZeneca R&D Charnwood for over 20 years and was instrumental in the development and success of hit to lead at Charnwood. He has a BSc (Hons) in biochemistry from the University of Bristol, a PhD on cardiac bioenergetics from the University of Leeds and undertook post-doctoral research on biological NMR at the University of Oxford.